A Phase 4 interventional study of transdermal GFR in AKI and GFR, sponsored by Bin Du. Not yet recruiting. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Bin Du · Phase 4, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this study is to learn if the TGFR device (which uses telmapirazin to continuously measure real-time GFR) works to provide accurate and dynamic kidney function assessment in critically ill adults with acute kidney injury (AKI). It will also learn how tGFR compares with the gold standard measured GFR (mGFR) and other commonly used estimate methods. The main questions it aims to answer are:
Researchers will compare tGFR to mGFR (iohexol clearance) to see if tGFR is a reliable alternative for bedside, continuous GFR monitoring. They will also compare tGFR against 4-hour creatinine clearance, keGFR, and eGFR to assess consistency across AKI stages.
Participants will:
1,693 studies on the registry are indexed under Acute Kidney Injury; 392 are open to participants now.
This study's planned enrollment of 50 is below the median of 100 across 819 interventional studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →Bin Du is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: transdermal GFR
The tGFR detection system comprised 3 distinct components as follows: (i) the fluorescent tracer agent, Lumitrace, (ii) a single small module containing both the light source and photo detector attached to the upper chest area using a biocompatible adhesive, and (iii) a display monitor that digitizes the acquired fluorescent intensity data and contains the algorithms to convert these data to GFR. Background endogenous fluorescence was acquired after attachment of the module to the chest, followed by a 7 ml i.v. bolus dose of Lumitrace. The monitor shows the fluorescence intensity as it is being acquired and then displays the determined tGFR after data acquisition is completed.
To validate the agreement of TGFR with mGFR in AKI patients at both the segmented and overall 0-12 hour levels.
Time frame: 12 hours
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jun 2026; primary completion for Dec 2026, 6 months later.
Of 46 non-industry phase 4 interventional studies under Acute Kidney Injury, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 57. This study's planned 6 months is below that.
Counting every sponsor, half of 47 studies reached it within 30 months; a quarter within 14 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.